Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan

Nozomu Kawashima, Minako Iida, Ritsuro Suzuki, Takahiro Fukuda, Yoshiko Atsuta, Yoshiko Hashii, Masami Inoue, Masao Kobayashi, Hiromasa Yabe, Keiko Okada, Souichi Adachi, Yuki Yuza, Keisei Kawa, Koji Kato

Research output: Contribution to journalArticle

Abstract

We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16% developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD.

Original languageEnglish
Pages (from-to)491-498
Number of pages8
JournalInternational journal of hematology
Volume109
Issue number4
DOIs
Publication statusPublished - Apr 5 2019

Fingerprint

Mycophenolic Acid
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Japan
Therapeutics
Hematologic Neoplasms
Immunosuppressive Agents
Infection
Surveys and Questionnaires
Neutropenia
Thrombocytopenia
Diarrhea
Tissue Donors
Safety

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation : a nationwide survey in Japan. / Kawashima, Nozomu; Iida, Minako; Suzuki, Ritsuro; Fukuda, Takahiro; Atsuta, Yoshiko; Hashii, Yoshiko; Inoue, Masami; Kobayashi, Masao; Yabe, Hiromasa; Okada, Keiko; Adachi, Souichi; Yuza, Yuki; Kawa, Keisei; Kato, Koji.

In: International journal of hematology, Vol. 109, No. 4, 05.04.2019, p. 491-498.

Research output: Contribution to journalArticle

Kawashima, Nozomu ; Iida, Minako ; Suzuki, Ritsuro ; Fukuda, Takahiro ; Atsuta, Yoshiko ; Hashii, Yoshiko ; Inoue, Masami ; Kobayashi, Masao ; Yabe, Hiromasa ; Okada, Keiko ; Adachi, Souichi ; Yuza, Yuki ; Kawa, Keisei ; Kato, Koji. / Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation : a nationwide survey in Japan. In: International journal of hematology. 2019 ; Vol. 109, No. 4. pp. 491-498.
@article{91fee52007904f1c9d81512dd3c70a52,
title = "Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan",
abstract = "We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29{\%} and 8.6{\%} of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16{\%} developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61{\%} had decreased grade. In the chronic GVHD treatment group, 36{\%} had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61{\%} patients. Major adverse events (AEs) were neutropenia (4.3{\%}), infection (3.5{\%}), thrombocytopenia (2.1{\%}), myelosuppression (2.1{\%}), and diarrhea (1.4{\%}). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD.",
author = "Nozomu Kawashima and Minako Iida and Ritsuro Suzuki and Takahiro Fukuda and Yoshiko Atsuta and Yoshiko Hashii and Masami Inoue and Masao Kobayashi and Hiromasa Yabe and Keiko Okada and Souichi Adachi and Yuki Yuza and Keisei Kawa and Koji Kato",
year = "2019",
month = "4",
day = "5",
doi = "10.1007/s12185-019-02601-5",
language = "English",
volume = "109",
pages = "491--498",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation

T2 - a nationwide survey in Japan

AU - Kawashima, Nozomu

AU - Iida, Minako

AU - Suzuki, Ritsuro

AU - Fukuda, Takahiro

AU - Atsuta, Yoshiko

AU - Hashii, Yoshiko

AU - Inoue, Masami

AU - Kobayashi, Masao

AU - Yabe, Hiromasa

AU - Okada, Keiko

AU - Adachi, Souichi

AU - Yuza, Yuki

AU - Kawa, Keisei

AU - Kato, Koji

PY - 2019/4/5

Y1 - 2019/4/5

N2 - We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16% developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD.

AB - We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16% developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD.

UR - http://www.scopus.com/inward/record.url?scp=85063904659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063904659&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02601-5

DO - 10.1007/s12185-019-02601-5

M3 - Article

C2 - 30694451

AN - SCOPUS:85063904659

VL - 109

SP - 491

EP - 498

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -